Elevance Health stock holds steady as Q2 earnings beat supports 2026 outlook

Elevance Health Inc. (ISIN US2855211023) stock is trading close to $390 as of August 18, 2026, after a recent earnings beat and firm full-year guidance helped underpin sentiment toward the health insurer.

The latest quarter reported on July 15, 2026 showed Elevance Health delivering earnings per share of $7.45, well ahead of the consensus estimate of $6.21, while revenue reached $49.83 billion in the same period.

For investors, the combination of double-digit year-to-date share price gains and a clear path toward full-year EPS of 27.07 in 2026 keeps Elevance Health stock aligned with a broadly positive analyst view.

Q2 2026 earnings beat sets the tone

Elevance Health’s most recent earnings release on July 15, 2026 covers the second quarter of 2026 and provides the key fundamental backdrop for the stock’s current trading range.

In that quarter, the company reported earnings per share of $7.45 versus analyst expectations at $6.21, delivering a positive surprise of $1.24 per share and signaling solid profitability despite elevated medical cost trends.

Quarterly revenue came in at $49.83 billion against analyst estimates of $48.88 billion, a difference of $0.95 billion that reflects slightly stronger-than-expected top-line performance.

On a year-over-year basis, that $49.83 billion revenue figure represents a 0.8 percent increase compared with the same quarter a year earlier, illustrating that growth is present but measured in Elevance Health’s current operating environment.

The quarter also showed a return on equity of 14.64 percent, paired with a net margin of 2.47 percent, giving investors a clearer view of the company’s ability to convert large premium volumes and services revenue into bottom-line earnings.

Guidance and analyst expectations for 2026

Beyond the Q2 2026 beat, current consensus data point to Elevance Health targeting full-year 2026 earnings per share of 27.07, based on the latest coverage from equity research teams.

Set against the reported trailing twelve-month earnings per share of 23.66 cited in recent market-data overviews, that 27.07 expectation implies further EPS growth during the remainder of 2026.

Analyst assessments compiled in these same sources assign Elevance Health an overall rating of Buy or Moderate Buy, reflecting that most covering analysts see upside from current levels rather than material downside risk.

The average published 12-month price target for the stock stands at $440.90, indicating potential upside of roughly 12 to 13 percent from the $390 to $391 trading zone highlighted in recent quote snapshots.

Some market-data pages even point to a slightly higher blended target in the mid-$440 range, emphasizing that consensus expectations still incorporate forward earnings growth and stable membership trends.

Elevance Health has also updated its full-year outlook in recent quarters, raising its earnings projections as rate updates, membership mix and medical cost acuity have aligned with internal assumptions and cost-control initiatives.

Share price, performance and valuation

Several quote services show Elevance Health trading in the $390 range during the latest session on August 18, 2026, with one live snapshot indicating a share price of $390.38 and another capturing an opening level of $390.69 on the New York Stock Exchange.

One intraday update lists a fair-value quote of $399.02 at 10:05 a.m. Eastern, with a separate feed recording Elevance Health stock at $400.32 later in the same session, underscoring that the shares have been fluctuating within a band of roughly $390 to $400 on August 18, 2026.

Data from a market portal show Elevance Health’s stock was trading at $350.59 at the beginning of 2026 and has since moved up to $390.69, an increase of 11.4 percent year to date.

This double-digit gain in 2026 places Elevance Health comfortably in positive territory for the year, even as health insurers navigate changing Medicare Advantage membership patterns and ongoing cost pressures.

In valuation terms, one comparative analysis notes that Elevance Health trades at a price-to-sales ratio of 0.44, a level that sits below or in line with some major peers and reflects the company’s substantial revenue base in relation to its market capitalization.

A separate performance comparison details that Elevance Health shares have risen 25.1 percent over a broader period examined alongside other large health-care issuers, pointing to strong multi-period performance and supporting the idea that the stock has delivered attractive returns over more than just the current calendar year.

Ownership trends and institutional flows

Recent filings and market updates indicate that institutional investors have been active in Elevance Health in 2026, adding positions in the insurer as part of broader health-care allocations.

One disclosed transaction reports a new $5.58 million investment in Elevance Health shares by a large asset manager, highlighting fresh capital coming into the stock.

Another filing shows an investment firm initiating a substantial $205.91 million position in Elevance Health, reinforcing the notion that institutions view the shares as a core holding within the health-insurance sector.

Additional updates describe multiple banks and asset managers purchasing blocks of Elevance Health stock, including a 943,054-share transaction and several smaller yet still meaningful trades in the tens of thousands of shares.

These flows contribute to a picture of strong institutional participation and suggest that professional investors see Elevance Health’s earnings trajectory and balance-sheet profile as attractive at current price levels.

Dividend profile and income appeal

Income-seeking investors are also watching Elevance Health’s dividend profile as part of the overall return case.

The company’s investor calendar for 2026 lists a dividend payable on June 25, 2026 for shareholders of record on June 10, 2026, indicating that Elevance Health continues to return cash to shareholders in the form of regular quarterly payouts.

Recent disclosures further reference a quarterly dividend of $1.72 per share that is scheduled to be paid on September 25, 2026, with a record date of September 10, 2026.

At a share price in the $390 zone, that $1.72 quarterly dividend translates into an annualized payout of $6.88, which in turn implies a forward dividend yield in the low-single-digit percent range.

For investors considering the stock as part of a diversified portfolio, the combination of consistent dividend payments and earnings growth offers a blend of income and capital appreciation potential.

Operating context and membership dynamics

Elevance Health’s operating context in 2026 is shaped by both premium growth and evolving membership patterns in key segments such as Medicare Advantage and commercial plans.

Recent sector commentary notes that Elevance Health has experienced a decline in Medicare Advantage membership since the third quarter of 2025, reflecting competitive dynamics and regulatory adjustments in that market.

Despite this shift, the company has raised its full-year earnings projections, indicating that stronger-than-expected rate updates, a membership mix aligned with internal assumptions and targeted actions to manage elevated cost trends are supporting profitability.

Management has emphasized that membership and acuity remain broadly consistent with the company’s expectations, suggesting that Elevance Health is adjusting its product offerings and pricing to maintain margin stability.

For investors, this backdrop means that headline membership declines in certain segments are being offset by disciplined underwriting, pricing and cost-control measures that sustain earnings growth.

Sector comparison and peer context

Within the broader U.S. health-care landscape, Elevance Health’s performance and valuation can be compared with other large managed-care and health-insurance names.

One recent article contrasting multiple health-related stocks indicates that Elevance Health shares have risen 25.1 percent over the period examined, compared with a 29.8 percent increase for another large health insurer in the same timeframe.

That comparison shows Elevance Health delivering strong absolute returns while slightly lagging the highest performer in a select peer group, a nuance that may matter to investors seeking relative value in the sector.

On price-to-sales, Elevance Health’s 0.44 multiple sits in a range that suggests the stock is not trading at an excessive premium to revenue, which is relevant for investors weighing valuation against expected growth in premiums and services revenue.

The sector-wide theme highlighted by recent coverage is that major health insurers, including Elevance Health, have managed to raise their outlooks despite higher costs and shifting membership, thanks to rate updates and targeted management of medical trends.

Business model and key offering

Elevance Health operates as a diversified health-benefits company, providing a mix of medical, pharmacy, behavioral and related services to individuals, employers and government programs across the United States.

A central element of Elevance Health’s business model is its suite of commercial and government health plans, which offer coverage options to millions of members under various brands and contracts.

Through these health plans, the company collects premiums and manages medical costs, leveraging data analytics, care-coordination programs and provider networks to balance affordability with access to care.

Elevance Health also offers integrated services such as pharmacy benefit management and specialty-care solutions, which help employers and health systems manage complex conditions and drug spending.

This integrated model is designed to generate both medical-cost savings and improved health outcomes, supporting Elevance Health’s ability to deliver recurring earnings and cash flow.

Stock positioning as of August 18, 2026

As of the most recent completed New York trading session referenced in quote feeds, Elevance Health stock closed at $390.88 on August 17, 2026, with the shares reported at that same price level in delayed quotes carrying a 4:00 p.m. Eastern timestamp.

Current market-data pages indicate a market capitalization in the mid-$80 billion range for Elevance Health at that $390.88 price, underscoring its status as a large-cap component of the U.S. health-care sector.

For investors, the combination of a recent Q2 2026 earnings beat, a forecast full-year EPS target of 27.07, an 11.4 percent year-to-date gain from $350.59 to around $390.69 and a modest forward dividend yield frames Elevance Health stock as a substantial, earnings-driven health insurer with ongoing income and growth potential in 2026.

Read more

Further details on Elevance Health’s latest earnings, dividend schedule and analyst expectations are available in current market-data and earnings-summary pages maintained by financial information providers.

Health plans as a core product

One representative offering within Elevance Health’s portfolio is its suite of commercial employer health plans, which provide comprehensive medical coverage, access to provider networks and integrated pharmacy benefits for workers and their families.

These plans typically combine preventive care, acute-care coverage and chronic-disease management programs, enabling employers to offer competitive benefits while Elevance Health manages claims, cost trends and care coordination.

By pairing these health plans with analytics and wellness initiatives, Elevance Health seeks to improve member health outcomes and reduce avoidable medical expenses, supporting the long-term sustainability of its business model.

Latest price context for Elevance Health stock

In the context of the latest available closing data, Elevance Health stock last finished regular trading at $390.88 on the New York Stock Exchange as of August 17, 2026, based on a delayed quote snapshot.

That closing level sits within the broader intraday range observed on August 18, 2026, where the shares traded between roughly $388 and $400, and continues to reflect the earnings and guidance story that has driven the stock’s 11.4 percent rise from $350.59 at the start of 2026.

Fact box

Company: Elevance Health Inc.

ISIN: US2855211023

Ticker: ELV

Exchange: NYSE

Price (as of August 17, 2026, 4:00 p.m. ET): $390.88 USD

Market cap: $84.63 billion (as of August 17, 2026)

Sector / Industry: Health care / Managed care

Index membership: S&P 500